Takeda continues non-core asset sell-off for $825M

Takeda Pharmaceuticals continues to combat its Shire acquisition-related debt by selling off another set of non-core assets to Hypera in Brazil, the company announced March 2.

What you should know:

1. Hypera gave the Japanese drugmaker $825 million for a number of over-the-counter and prescription pharmaceutical products sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama and Peru.

2. Takeda has completed five similar transactions recently. The company aims to divest $10 billion of its non-core assets to pay off its debt.

3. After acquiring Shire in January 2019, Takeda became one of the largest and most indebted drugmakers in the world.

More articles on surgery centers:
PE-backed Prism Vision snags Maryland eye group — 4 insights
Florida ASC buyer projects $18M profit in 1st year: 5 details
Physician-owned eye group acquires California practice 

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Webinars

Featured Whitepapers